Prostate CancerPhase 2/3NCT04263025
AMNIOX CORD Study - Radical Prostatectomy With and Without Cryopreserved Umbilical Cord Allograft
A Phase 2/3 study testing Cryopreserved Umbilical Cord Allograft and Robot-Assisted Radical Prostatectomy in people with Prostate Cancer, run by Hackensack Meridian Health at 1 site in United States.
Trial summary
This study aims at evaluating if placement of CLARIX® CORD 1K during robotic prostatectomy decreases the time to achieve complete erectile and urinary function after the surgery. As part of the study, the patient will be asked to answer various questions after the surgery regarding sexual and urinary function. Read more about this study
- Who is it for?
- Ages 30 to 70 years, men only
- Conditions the study is for
- Prostate Cancer
- What is being tested?
- Cryopreserved Umbilical Cord Allograft and Robot-Assisted Radical Prostatectomy
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- 1 siteUnited States
- Study dates
- 30 Jan 2020to 1 Apr 2027
- Phase
- Phase 2/3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 70 years
- Men only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male aged between 30 and 70 years old
- Primary diagnosis of organ confined prostate cancer
- Scheduled to undergo bilateral, nerve-sparing RARP
- Patient has ICIQ-SF score <6
- Patient has no erectile dysfunction (defined as IIEF-6 score ≥ 26)
- Patient is willing to return for all visits as defined in the protocol
- Patient is willing to follow the instruction of the Investigator
- Patient has provided written informed consent
Who cannot join
- Previous history of pelvic radiation
- Previous history of simple prostatectomy or transurethral prostate surgery
- Previous history of systemic therapy for prostate cancer
- Patient has neurogenic bladder
- Body weight less than 50 kg (110 pounds) or a body mass index greater than 40 kg/m2
- History of open pelvic surgery within 5 years except for hernia repair
Show all 10Show fewer
- Scheduled at the time of screening to undergo chemotherapy, radiation, hormone therapy, or open surgery during the study period.
- Any neurologic disorder or psychiatric disorder (e.g., Parkinson's Multiple Sclerosis, etc.) that might confound postsurgical assessments
- Received administration of an investigational drug within 30 days prior to study, and/or has planned administration of another investigational product or procedure during participation in this study
- Previous history of anaphylaxis or hypersensitivity to liposomal amphotericin- B
Trial locations and contacts
1 site in 1 country.
United States1 site
Hackensack University Medical Center
Hackensack, New Jersey, 07601
About this study
Official title: Prospective, Controlled Study Evaluating Recovery of Potency and Continence Following Robot-Assisted Radical Prostatectomy With and Without Cryopreserved Umbilical Cord Allograft
This study aims at evaluating if placement of CLARIX® CORD 1K during robotic prostatectomy decreases the time to achieve complete erectile and urinary function after the surgery. As part of the study, the patient will be asked to answer various questions after the surgery regarding sexual and urinary function.
Read the detailed description
One hundred male patients who are scheduled for bilateral, nerve-sparing RARP that meet the eligibility criteria will be enrolled. These patients will be equally randomized (1:1) into two groups (n=50/group): one group will receive adjunctive CLARIX® CORD 1K (Amniox Medical, Inc., Miami, FL) during RARP, while the other group will undergo RARP without adjunctive CLARIX® CORD 1K. Subject stratification will be performed based on the surgeon that will be performing the RARP. All patients will be given the same routine preoperative, perioperative and postoperative evaluation and care aside from the CLARIX CORD 1K placement in the treatment group during RARP. RARP will be performed at Hackensack University Medical Center (30 Prospect Ave, Hackensack, NJ 07601) and follow up visits performed at Hackensack University Medical Group Urology (360 Essex Street, Suite 403, Hackensack, NJ 07601) or New Jersey Urology (255 W. Spring Valley Avenue Suite 101, Maywood, NJ 07607).
Two weeks prior to the RARP surgery, subjects are instructed to take low-dose oral phosphodiesterase type 5 inhibitors (i.e. 20 mg q.d. sildenafil citrate or 5 mg q.d. tadalafil) and perform standardized Kegel exercises (3x/day) which is our current standard care protocol. RARP surgery will be performed at Hackensack University Medical Center (Hackensack, NJ). The following are the key aspects of the RARP surgical technique which will be adhered to by all surgeons: 1) dissection of the bladder neck, seminal vesicles and vasa deferentia; 2) dissection of the neuroplexus from the posterior Denonvilliers' fascia and lateral prostatic fascia leaving the nerves intact; 3) division of the prostatic pedicles without cautery; 4) transection of the dorsal venous complex; and 5) urethrovesical anastomosis. More specifically, surgical technique includes exposing the prostate in the space of Retzius with the traditional anterior approach.
The prostatovesical tissue is dissected with monopolar electrocautery scissors with entry into the bladder proximal to the prostatovesical junction. The bladder neck is transected in the standard fashion followed by posterior dissection of the seminal vesicles and vasa deferentia.
Electrocautery is kept to a minimum when dissecting the seminal vesicles to avoid damage to the neuroplexus. (Note: each step hereafter must be performed by the PI or Sub-investigators, e.g. not a Resident Physician). A posterior surgical plane is then created between the rectum and prostate dorsally working from a medial to lateral direction and maintaining at least 1 layer of Denonvilliers' fascia on the rectal wall. The endopelvic fascia is then excised from lateral prostate and carried to capsule to create a plane of dissection immediately alongside the prostatic capsule and keeping the nerves attached laterally to the endopelvic fascia. Athermal division of each prostatic pedicle will be performed. Clips or suture may be placed on each pedicle at the discretion of the surgeon. The apex of the prostate is then dissected athermally sparing the neuroplexus. The dorsal vein complex is proximally transected with electrocautery while using the fourth arm to place traction on the prostate to define the space between the dorsal vein complex and the apex of the prostate. Apically, the prostate is divided from the urethra (paying special attention to the sphincter muscle and posterior lateral nerve bundle on each side) allowing the prostate to be removed. Once free, the prostate is placed in a collection bag and a drain is used for a certain period at the discretion of the surgeon.
Surgical site bleeding is managed using standard surgical techniques with sutures or cellulose polymer. If the patient is randomized to the treatment group, CLARIX CORD 1K is placed flat over the neuroplexis at the 5 and 7 clock position where the largest concentration of nerves exist. Sutures may be used to secure the CLARIX in place if necessary and cellulose polymer (Surgicel, Ethicon, Somerville, NJ) can be placed over the CLARIX CORD at the discretion of the physician.
At this point the bladder neck will be reconstructed as necessary to maintain a lumen of approximately 30 french. The vesicourethral anastomosis is performed using a V-lock barbed suture. The anastomosis will be tested by filling bladder to confirm the absence of leakage. If indicated, a bilateral pelvic lymph node dissection is performed (with clips at the discretion of the physician) using standard (borders along the external iliac artery and vein, obturator fossa, obturator nerve and pubic bone) or extended (borders additionally include internal iliac artery) technique at the discretion of the physician. Bleeding will be adequately managed. Postoperatively, all subjects are instructed to take low-dose oral phosphodiesterase type 5 inhibitors (i.e. 20 mg q.d. sildenafil citrate or 5 mg q.d. tadalafil) and perform standardized Kegel exercises (3x/day) following urethral catheter removal. When patients are sexually active, they may increase to full dosage of oral phosphodiesterase type 5 inhibitors up to twice a week. At 3 months after RARP, and if patients have severe or worse incontinence (defined as ICIQ score of >12) and desire additional treatment for urinary incontinence,[42] they will undergo pelvic floor therapy. Subjects will return for follow up visits at 6 weeks (±1 week), 3 months (±2 weeks), 6 months (±3 weeks) and 12 months (±4 weeks) when data will be collected.
Patient reported outcomes will be assessed including continence, potency, and satisfaction. Occurrence of adverse events, number of readmissions, and need for reintervention will also be recorded. Measurement of serum PSA levels will also be performed.
- Conditions
- Prostate Cancer
- Being tested
- Cryopreserved Umbilical Cord Allograft, Robot-Assisted Radical Prostatectomy
- Keywords
- Prostate cancer, Bilateral, nerve-sparing prostatectomy, Prostatectomy
- Medical subject headings
- Prostatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cryopreserved Umbilical Cord AllograftBiological
CLARIX® CORD 1K (Amniox Medical, Miami, FL) is an umbilical cord allograft processed using the patented CRYOTEK™ process by TissueTech Inc. to devitalize all living cells but retain the natural structural and biological characteristics relevant to this tissue [43]. CLARIX® CORD 1K (6x3 cm in size) will be cut into two longitudinal pieces (1.5 cm in width) and placed circumferentially around each NVB as a nerve wrap during RARP. CLARIX® CORD 1K has been in market since 2013 in the United States as a "361 human cell and tissue-based product (HCT/P)" and is aseptically processed in compliance with current Good Tissue Practices (cGTP) as outlined in 21 CFR Part 1271.
Robot-Assisted Radical ProstatectomyProcedure or surgery
Robot-Assisted Radical Prostatectomy (RARP) is the most common surgical technique used to treat clinically localized prostate cancer however robot-assisted radical prostatectomy
| Study group | Role | What they receive |
|---|---|---|
| CLARIX CORD 1K | Experimental | They will receive adjunctive CLARIX® CORD 1K (Amniox Medical, Inc., Miami, FL) during Robot-Assisted Radical Prostatectomy (RARP). Receives: Biological: Cryopreserved Umbilical Cord Allograft; Procedure: Robot-Assisted Radical Prostatectomy |
| Controls | Active comparator | They will undergo RARP without adjunctive CLARIX® CORD 1K. Receives: Procedure: Robot-Assisted Radical Prostatectomy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Erectile function
Erectile function will be evaluated using the International Index of Erectile Function (IIEF)
Measured: At three months post surgery
Erectile function
Erectile function will be evaluated using the International Index of Erectile Function (IIEF)
Measured: At six months post surgery
Erectile function
Erectile function will be evaluated using the International Index of Erectile Function (IIEF)
Measured: At twelve months post surgery
Secondary outcomes (29)
Potency endpoint
IIEF-6 Levels at 6 weeks post-op between the two treatment groups
Measured: 6 weeks post op
Potency endpoint
IIEF-6 Levels at 3 months post-op between the two treatment groups
Measured: 3 months post op
Potency endpoint
IIEF-6 Levels at 6 months post-op between the two treatment groups
Measured: 6 months post op
Potency endpoint
IIEF-6 Levels at 12 months post-op between the two treatment groups
Measured: 12 months post op
Return to continence
Continence will be evaluated using the International Consultation of Incontinence Questionnaire - Short Form (ICIQ-SF)
Measured: At 6 weeks post surgery
Return to continence
Continence will be evaluated using the International Consultation of Incontinence Questionnaire - Short Form (ICIQ-SF)
Measured: At three months post surgery
Return to continence
Continence will be evaluated using the International Consultation of Incontinence Questionnaire - Short Form (ICIQ-SF)
Measured: At six months post surgery
Return to continence
Continence will be evaluated using the International Consultation of Incontinence Questionnaire - Short Form (ICIQ-SF)
Measured: At twelve months post surgery
Pad Weight
Changes from baseline of average pad weight to 6 weeks post-op between treatment groups
Measured: 6 weeks post op
Pad Count
Proportion of patients that wear 0 or 1 safety pads; 1-2 safety pads; and >2 safety pads per day
Measured: 6 weeks post op
Pad Weight
Changes from baseline of average pad weight to 3 months post-op between treatment groups
Measured: 3 months post op
Pad Count
Proportion of patients that wear 0 or 1 safety pads; 1-2 safety pads; and >2 safety pads per day
Measured: 3 months post op
Pad Weight
Changes from baseline of average pad weight to 6 months post-op between treatment groups
Measured: 6 months post op
Pad Count
Proportion of patients that wear 0 or 1 safety pads; 1-2 safety pads; and >2 safety pads per day
Measured: 6 months post op
Pad Weight
Changes from baseline of average pad weight to 12 months post-op between treatment groups
Measured: 12 months post op
Pad Count
Proportion of patients that wear 0 or 1 safety pads; 1-2 safety pads; and >2 safety pads per day
Measured: 12 months post op
Sexual encounter
Patients will be asked to complete the Sexual Encounter Profile (SEP) Diary to document after each sexual attempt
Measured: At three months post surgery
Sexual encounter
Patients will be asked to complete the Sexual Encounter Profile (SEP) Diary to document after each sexual attempt
Measured: At six months post surgery
Sexual encounter
Patients will be asked to complete the Sexual Encounter Profile (SEP) Diary to document after each sexual attempt
Measured: At twelve months post surgery
Biochemical recurrence endpoint
Proportion of patients with biochemical recurrence at 6 weeks post-op between groups.
Measured: 6 weeks post-op
Biochemical recurrence endpoint
Proportion of patients with biochemical recurrence at 3 months post-op between groups.
Measured: 3 months post-op
Biochemical recurrence endpoint
Proportion of patients with biochemical recurrence at 6 months post-op between groups.
Measured: 6 months post-op
Biochemical recurrence endpoint
Proportion of patients with biochemical recurrence at 12 months post-op between groups.
Measured: 12 months post-op
Patient intercourse satisfaction endpoint
Patient satisfaction using Likert score at 6 weeks post-op between groups
Measured: 6 weeks post op
Patient intercourse satisfaction endpoint
Patient satisfaction using Likert score at 3 months post-op between groups
Measured: 3 months post op
Patient intercourse satisfaction endpoint
Patient satisfaction using Likert score at 6 months post-op between groups
Measured: 6 months post op
Patient intercourse satisfaction endpoint
Patient satisfaction using Likert score at 12 months post-op between groups
Measured: 12 months post op
Failure Events of Following RARP endpoint
Incidence of readmission for hospital stay at 2 weeks post-op between groups.
Measured: 2 weeks post-op
Failure Events of Following RARP endpoint
Number of surgical interventions at 2 weeks post-op between groups
Measured: 2 weeks post-op
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Feb 2020
- Study start30 Jan 2020
- Primary completion1 Apr 2027 (estimated)
- Study completion1 Apr 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Prostate CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2/3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 100 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hackensack Meridian Health
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Michael Stifelman, MD, Principal investigator, Chair of Urology Department
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04263025
- Sponsor's protocol ID
- Pro2019-0452
- Status last verified
- May 2026
- First submitted
- 7 Feb 2020
- Last updated
- 26 May 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective, Controlled Study Evaluating Recovery of Potency and Continence Following Robot-Assisted Radical Prostatectomy With and Without Cryopreserved Umbilical Cord Allograft
- ClinicalTrials.gov ID
- NCT04263025
- Acronym / sponsor ID
- Pro2019-0452
- Conditions
- Prostate Cancer
- Keywords
- Prostate cancer, Bilateral, nerve-sparing prostatectomy, Prostatectomy
- Phase
- Phase 2/3
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 100 participants (actual)
- Lead sponsor
- Hackensack Meridian HealthUniversity, hospital or other
- Study start
- 30 Jan 2020 (actual)
- Primary completion
- 1 Apr 2027 (estimated)
- Study completion
- 1 Apr 2027 (estimated)
- First posted
- 10 Feb 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims at evaluating if placement of CLARIX® CORD 1K during robotic prostatectomy decreases the time to achieve complete erectile and urinary function after the surgery. As part of the study, the patient will be asked to answer various questions after the surgery regarding sexual and urinary function.
Detailed description
One hundred male patients who are scheduled for bilateral, nerve-sparing RARP that meet the eligibility criteria will be enrolled. These patients will be equally randomized (1:1) into two groups (n=50/group): one group will receive adjunctive CLARIX® CORD 1K (Amniox Medical, Inc., Miami, FL) during RARP, while the other group will undergo RARP without adjunctive CLARIX® CORD 1K. Subject stratification will be performed based on the surgeon that will be performing the RARP. All patients will be given the same routine preoperative, perioperative and postoperative evaluation and care aside from the CLARIX CORD 1K placement in the treatment group during RARP. RARP will be performed at Hackensack University Medical Center (30 Prospect Ave, Hackensack, NJ 07601) and follow up visits performed at Hackensack University Medical Group Urology (360 Essex Street, Suite 403, Hackensack, NJ 07601) or New Jersey Urology (255 W. Spring Valley Avenue Suite 101, Maywood, NJ 07607).
Two weeks prior to the RARP surgery, subjects are instructed to take low-dose oral phosphodiesterase type 5 inhibitors (i.e. 20 mg q.d. sildenafil citrate or 5 mg q.d. tadalafil) and perform standardized Kegel exercises (3x/day) which is our current standard care protocol. RARP surgery will be performed at Hackensack University Medical Center (Hackensack, NJ). The following are the key aspects of the RARP surgical technique which will be adhered to by all surgeons: 1) dissection of the bladder neck, seminal vesicles and vasa deferentia; 2) dissection of the neuroplexus from the posterior Denonvilliers' fascia and lateral prostatic fascia leaving the nerves intact; 3) division of the prostatic pedicles without cautery; 4) transection of the dorsal venous complex; and 5) urethrovesical anastomosis. More specifically, surgical technique includes exposing the prostate in the space of Retzius with the traditional anterior approach.
The prostatovesical tissue is dissected with monopolar electrocautery scissors with entry into the bladder proximal to the prostatovesical junction. The bladder neck is transected in the standard fashion followed by posterior dissection of the seminal vesicles and vasa deferentia.
Electrocautery is kept to a minimum when dissecting the seminal vesicles to avoid damage to the neuroplexus. (Note: each step hereafter must be performed by the PI or Sub-investigators, e.g. not a Resident Physician). A posterior surgical plane is then created between the rectum and prostate dorsally working from a medial to lateral direction and maintaining at least 1 layer of Denonvilliers' fascia on the rectal wall. The endopelvic fascia is then excised from lateral prostate and carried to capsule to create a plane of dissection immediately alongside the prostatic capsule and keeping the nerves attached laterally to the endopelvic fascia. Athermal division of each prostatic pedicle will be performed. Clips or suture may be placed on each pedicle at the discretion of the surgeon. The apex of the prostate is then dissected athermally sparing the neuroplexus. The dorsal vein complex is proximally transected with electrocautery while using the fourth arm to place traction on the prostate to define the space between the dorsal vein complex and the apex of the prostate. Apically, the prostate is divided from the urethra (paying special attention to the sphincter muscle and posterior lateral nerve bundle on each side) allowing the prostate to be removed. Once free, the prostate is placed in a collection bag and a drain is used for a certain period at the discretion of the surgeon.
Surgical site bleeding is managed using standard surgical techniques with sutures or cellulose polymer. If the patient is randomized to the treatment group, CLARIX CORD 1K is placed flat over the neuroplexis at the 5 and 7 clock position where the largest concentration of nerves exist. Sutures may be used to secure the CLARIX in place if necessary and cellulose polymer (Surgicel, Ethicon, Somerville, NJ) can be placed over the CLARIX CORD at the discretion of the physician.
At this point the bladder neck will be reconstructed as necessary to maintain a lumen of approximately 30 french. The vesicourethral anastomosis is performed using a V-lock barbed suture. The anastomosis will be tested by filling bladder to confirm the absence of leakage. If indicated, a bilateral pelvic lymph node dissection is performed (with clips at the discretion of the physician) using standard (borders along the external iliac artery and vein, obturator fossa, obturator nerve and pubic bone) or extended (borders additionally include internal iliac artery) technique at the discretion of the physician. Bleeding will be adequately managed. Postoperatively, all subjects are instructed to take low-dose oral phosphodiesterase type 5 inhibitors (i.e. 20 mg q.d. sildenafil citrate or 5 mg q.d. tadalafil) and perform standardized Kegel exercises (3x/day) following urethral catheter removal. When patients are sexually active, they may increase to full dosage of oral phosphodiesterase type 5 inhibitors up to twice a week. At 3 months after RARP, and if patients have severe or worse incontinence (defined as ICIQ score of >12) and desire additional treatment for urinary incontinence,[42] they will undergo pelvic floor therapy. Subjects will return for follow up visits at 6 weeks (±1 week), 3 months (±2 weeks), 6 months (±3 weeks) and 12 months (±4 weeks) when data will be collected.
Patient reported outcomes will be assessed including continence, potency, and satisfaction. Occurrence of adverse events, number of readmissions, and need for reintervention will also be recorded. Measurement of serum PSA levels will also be performed.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| CLARIX CORD 1K | Experimental | Biological: Cryopreserved Umbilical Cord Allograft, Procedure: Robot-Assisted Radical ProstatectomyThey will receive adjunctive CLARIX® CORD 1K (Amniox Medical, Inc., Miami, FL) during Robot-Assisted Radical Prostatectomy (RARP). |
| Controls | Active comparator | Procedure: Robot-Assisted Radical ProstatectomyThey will undergo RARP without adjunctive CLARIX® CORD 1K. |
Who may qualify
- Ages
- 30 to 70 years
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Male aged between 30 and 70 years old
- Primary diagnosis of organ confined prostate cancer
- Scheduled to undergo bilateral, nerve-sparing RARP
- Patient has ICIQ-SF score <6
- Patient has no erectile dysfunction (defined as IIEF-6 score ≥ 26)
Key exclusion criteria (10 listed)
- Previous history of pelvic radiation
- Previous history of simple prostatectomy or transurethral prostate surgery
- Previous history of systemic therapy for prostate cancer
- Patient has neurogenic bladder
- Body weight less than 50 kg (110 pounds) or a body mass index greater than 40 kg/m2
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cryopreserved Umbilical Cord AllograftCLARIX® CORD 1K (Amniox Medical, Miami, FL) is an umbilical cord allograft processed using the patented CRYOTEK™ process by TissueTech Inc. to devitalize all living cells but retain the natural structural and biological characteristics relevant to this tissue [43]. CLARIX® CORD 1K (6x3 cm in size) will be cut into two longitudinal pieces (1.5 cm in width) and placed circumferentially around each NVB as a nerve wrap during RARP. CLARIX® CORD 1K has been in market since 2013 in the United States as a "361 human cell and tissue-based product (HCT/P)" and is aseptically processed in compliance with current Good Tissue Practices (cGTP) as outlined in 21 CFR Part 1271. | Biological | CLARIX CORD 1K |
| Robot-Assisted Radical ProstatectomyRobot-Assisted Radical Prostatectomy (RARP) is the most common surgical technique used to treat clinically localized prostate cancer however robot-assisted radical prostatectomy | Procedure or surgery | CLARIX CORD 1K, Controls |
Primary outcome
Erectile function
Time frame: At three months post surgery
Erectile function will be evaluated using the International Index of Erectile Function (IIEF)
Erectile function
Time frame: At six months post surgery
Erectile function will be evaluated using the International Index of Erectile Function (IIEF)
Erectile function
Time frame: At twelve months post surgery
Erectile function will be evaluated using the International Index of Erectile Function (IIEF)
29 secondary outcomes
Potency endpoint
Time frame: 6 weeks post op
Potency endpoint
Time frame: 3 months post op
Potency endpoint
Time frame: 6 months post op
Potency endpoint
Time frame: 12 months post op
Return to continence
Time frame: At 6 weeks post surgery
Return to continence
Time frame: At three months post surgery
Return to continence
Time frame: At six months post surgery
Return to continence
Time frame: At twelve months post surgery
Pad Weight
Time frame: 6 weeks post op
Pad Count
Time frame: 6 weeks post op
Pad Weight
Time frame: 3 months post op
Pad Count
Time frame: 3 months post op
Pad Weight
Time frame: 6 months post op
Pad Count
Time frame: 6 months post op
Pad Weight
Time frame: 12 months post op
Pad Count
Time frame: 12 months post op
Sexual encounter
Time frame: At three months post surgery
Sexual encounter
Time frame: At six months post surgery
Sexual encounter
Time frame: At twelve months post surgery
Biochemical recurrence endpoint
Time frame: 6 weeks post-op
Biochemical recurrence endpoint
Time frame: 3 months post-op
Biochemical recurrence endpoint
Time frame: 6 months post-op
Biochemical recurrence endpoint
Time frame: 12 months post-op
Patient intercourse satisfaction endpoint
Time frame: 6 weeks post op
Patient intercourse satisfaction endpoint
Time frame: 3 months post op
Patient intercourse satisfaction endpoint
Time frame: 6 months post op
Patient intercourse satisfaction endpoint
Time frame: 12 months post op
Failure Events of Following RARP endpoint
Time frame: 2 weeks post-op
Failure Events of Following RARP endpoint
Time frame: 2 weeks post-op
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 May 2026.
- Individual participant dataSharing planned: No
Related trials for Prostate Cancer
RecruitingPhase 2
The COSMYC Trial (COmbined Suppression of MYC)
Metastatic Castration-resistant Prostate Cancer
Not yet recruitingPhase 3
A Study of JNJ-101556143 With Best Supportive Care in Participants With Metastatic Prostate Cancer
Prostatic Neoplasms
RecruitingPhase 1/2
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
RecruitingObservational study
PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan
Metastatic Prostate Cancer
RecruitingPhase 2
Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
Prostate Adenocarcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Michael Stifelman, MD principal investigator
Chair of Urology Department
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2/3 study testing Cryopreserved Umbilical Cord Allograft and Robot-Assisted Radical Prostatectomy in people with Prostate Cancer, run by Hackensack Meridian Health at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 26 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Erectile function (time frame: At three months post surgery). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 May 2026.